Ask OpenScientist

Ask a research question about Pertussis. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

5
Pathophys.
6
Phenotypes
6
Pathograph
2
Medical Actions

Pathophysiology

5
Bordetella pertussis Respiratory Colonization
Bordetella pertussis colonizes the ciliated epithelium of the respiratory tract and, through its virulence factors, subverts host immune defenses to establish infection. This colonization is the proximal event from which both toxin-mediated disease and the antibiotic-target biology follow.
ciliated airway epithelial cell CL:0000064
adhesion of symbiont to host GO:0044406
Show evidence (1 reference)
PMID:41893571 SUPPORT Other
"PTx works in concert with the bacterium's adenylate cyclase toxin (ACT) to subvert immune defenses and establish infection."
Establishes that B. pertussis virulence factors subvert immune defenses to establish respiratory infection. Evidence source is OTHER as this is a review article.
Pertussis Toxin-Mediated Disruption of Host Gi Signaling
Pertussis toxin, an AB5-type exotoxin, uses its enzymatic A subunit to ADP-ribosylate the alpha-subunit of inhibitory G proteins (Gαi), preventing receptor-induced inhibition of adenylyl cyclase and causing unrestrained cAMP accumulation in host cells — a canonical mechanism underlying many pertussis disease manifestations.
response to toxic substance GO:0009636
Show evidence (2 references)
PMID:41893571 SUPPORT Other
"Pertussis toxin (PTx) is a major virulence factor of Bordetella pertussis and an AB5-type exotoxin that disrupts host signaling."
Identifies pertussis toxin as the major AB5 exotoxin virulence factor that disrupts host signaling. Evidence source is OTHER as this is a review article.
PMID:41893571 SUPPORT Other
"Its enzymatic A subunit ADP-ribosylates the α-subunit of inhibitory G proteins (Gαi), preventing them from mediating receptor-induced inhibition of adenylyl cyclase (AC). This leads to unrestrained cAMP accumulation in host cells"
Details the molecular mechanism — ADP-ribosylation of Gαi causing unrestrained cAMP accumulation. Evidence source is OTHER as this is a review article.
Paroxysmal Coughing Illness
The clinical syndrome of pertussis is a paroxysmal coughing illness, classically with an inspiratory whoop and post-tussive emesis. In young infants it may manifest as cyanosis or facial flushing during coughing fits and apnea, and is associated with marked leukocytosis.
inflammatory response GO:0006954 ↑ INCREASED
respiratory system UBERON:0001004
Show evidence (1 reference)
PMID:41963827 SUPPORT Human Clinical
"presented with paroxysmal coughing"
Clinical cohort documenting paroxysmal coughing as the predominant presentation of pertussis. Evidence source is HUMAN_CLINICAL as this is a clinical cohort study.
Bacterial Ribosomal Translation (Macrolide Target)
B. pertussis depends on its bacterial ribosome for protein synthesis. Macrolides (e.g., azithromycin), the conventional antibiotics for pertussis, bind the 50S ribosomal subunit and block bacterial protein synthesis — the molecular target underlying antibiotic therapy (which reduces transmissibility more than it alters the toxin-driven cough once established).
translation GO:0006412
Show evidence (1 reference)
PMID:24336183 SUPPORT Other
"The ribosome is one of the main antibiotic targets in the bacterial cell."
Establishes the bacterial ribosome as the target of macrolides and other protein-synthesis inhibitors, the step this node represents. Evidence source is OTHER as this is a review article.
Emerging Macrolide Resistance
Macrolide-resistant B. pertussis is an emerging concern in some regions, which can render azithromycin ineffective and shift treatment toward alternatives such as trimethoprim-sulfamethoxazole.
response to antibiotic GO:0046677
Show evidence (1 reference)
PMID:41963827 SUPPORT In Vitro
"high-level resistance to azithromycin but sensitivity to trimethoprim-sulfamethoxazole, levofloxacin, doxycycline"
In vitro drug-susceptibility testing of B. pertussis isolates showing high-level azithromycin resistance with retained sensitivity to alternatives. Evidence source is IN_VITRO as this is an in vitro susceptibility assay of isolates (in this cohort all 25 isolates were azithromycin-resistant, grounding the "in some regions" caveat).

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Pertussis Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.

Phenotypes

6
Blood 1
Leukocytosis Increased total leukocyte count HP:0001974
Show evidence (1 reference)
PMID:41963827 SUPPORT Human Clinical
"elevated white blood cell count"
Elevated white blood cell count was an independent risk factor for severe pertussis. Evidence source is HUMAN_CLINICAL as this is a clinical cohort study.
Digestive 1
Post-tussive Vomiting Vomiting HP:0002013
Show evidence (1 reference)
PMID:41963827 SUPPORT Human Clinical
"post-tussive emesis"
Post-tussive emesis was documented in the clinical cohort. Evidence source is HUMAN_CLINICAL as this is a clinical cohort study.
Integument 1
Cyanosis Cyanosis HP:0000961
Show evidence (1 reference)
PMID:41963827 SUPPORT Human Clinical
"manifested cyanosis or facial flushing during coughing"
Over half of hospitalized cases manifested cyanosis or facial flushing during coughing. Evidence source is HUMAN_CLINICAL as this is a clinical cohort study.
Metabolism 1
Fever Fever HP:0001945
Respiratory 1
Apnea Apnea HP:0002104
Show evidence (1 reference)
PMID:41963827 SUPPORT Human Clinical
"had apnea"
Apnea was documented among hospitalized pertussis cases. Evidence source is HUMAN_CLINICAL as this is a clinical cohort study.
Other 1
Whooping Cough Whooping cough HP:0031247
Show evidence (1 reference)
PMID:41963827 SUPPORT Human Clinical
"presented with paroxysmal coughing"
Most hospitalized cases presented with paroxysmal coughing. Evidence source is HUMAN_CLINICAL as this is a clinical cohort study.
💊

Medical Actions

2
Azithromycin
Action: Pharmacotherapy NCIT:C15986
Agent: azithromycin CHEBI:2955
Macrolide antibiotic that binds the 50S bacterial ribosome and inhibits protein synthesis; the conventional antibiotic for pertussis, primarily reducing transmissibility. Emerging macrolide-resistant B. pertussis in some regions can necessitate alternatives such as trimethoprim-sulfamethoxazole.
Mechanism Target:
INHIBITS Bacterial Ribosomal Translation (Macrolide Target) — Azithromycin binds the 50S ribosome and arrests B. pertussis protein synthesis, clearing carriage and reducing transmission.
Pertussis Vaccination
Action: vaccination MAXO:0001017
Acellular pertussis vaccination (DTaP in infants/children, Tdap boosters including maternal immunization) is the key strategy for preventing severe pertussis, particularly in young infants.
Show evidence (1 reference)
PMID:41963827 SUPPORT Human Clinical
"timely completion of the primary pertussis vaccination series in infants remains a key strategy for preventing severe pertussis"
The cohort concludes that timely primary pertussis vaccination is key to preventing severe disease. Evidence source is HUMAN_CLINICAL as this is a clinical cohort study.
{ }

Source YAML

click to show
name: Pertussis
creation_date: "2026-06-28T00:00:00Z"
description: >
  Pertussis (whooping cough) is an acute, highly contagious respiratory infection
  caused by the bacterium Bordetella pertussis. After colonizing the ciliated
  respiratory epithelium, the organism elaborates virulence factors — chiefly
  pertussis toxin (an AB5 exotoxin that ADP-ribosylates the inhibitory G protein
  Gαi, driving unrestrained cAMP accumulation) acting in concert with adenylate
  cyclase toxin — that subvert host defenses and produce the characteristic
  paroxysmal coughing illness with inspiratory whoop and post-tussive emesis.
  Disease is most severe in unvaccinated young infants, who may develop apnea,
  cyanosis, and marked leukocytosis. It is vaccine-preventable (DTaP/Tdap), and
  macrolides are the conventional antibiotic, though macrolide resistance is
  emerging in some regions.
category: Infectious Disease
parents:
- Bacterial Respiratory Infection
synonyms:
- Whooping cough
- Bordetella pertussis infection
disease_term:
  preferred_term: pertussis
  term:
    id: MONDO:0005077
    label: pertussis
pathophysiology:
- name: Bordetella pertussis Respiratory Colonization
  role: trigger
  description: >
    Bordetella pertussis colonizes the ciliated epithelium of the respiratory
    tract and, through its virulence factors, subverts host immune defenses to
    establish infection. This colonization is the proximal event from which both
    toxin-mediated disease and the antibiotic-target biology follow.
  cell_types:
  - preferred_term: ciliated airway epithelial cell
    term:
      id: CL:0000064
      label: ciliated cell
  biological_processes:
  - preferred_term: adhesion of symbiont to host
    term:
      id: GO:0044406
      label: adhesion of symbiont to host
  evidence:
  - reference: PMID:41893571
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      PTx works in concert with the bacterium's adenylate cyclase toxin (ACT) to
      subvert immune defenses and establish infection.
    explanation: >-
      Establishes that B. pertussis virulence factors subvert immune defenses to
      establish respiratory infection. Evidence source is OTHER as this is a review
      article.
  downstream:
  - target: Pertussis Toxin-Mediated Disruption of Host Gi Signaling
    description: >-
      The colonizing organism elaborates pertussis toxin, which disrupts host cell
      signaling.
  - target: Bacterial Ribosomal Translation (Macrolide Target)
    description: >-
      The organism's ribosome is the target of macrolide antibiotic therapy.

- name: Pertussis Toxin-Mediated Disruption of Host Gi Signaling
  role: effector
  description: >
    Pertussis toxin, an AB5-type exotoxin, uses its enzymatic A subunit to
    ADP-ribosylate the alpha-subunit of inhibitory G proteins (Gαi), preventing
    receptor-induced inhibition of adenylyl cyclase and causing unrestrained cAMP
    accumulation in host cells — a canonical mechanism underlying many pertussis
    disease manifestations.
  biological_processes:
  - preferred_term: response to toxic substance
    term:
      id: GO:0009636
      label: response to toxic substance
  evidence:
  - reference: PMID:41893571
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Pertussis toxin (PTx) is a major virulence factor of Bordetella pertussis
      and an AB5-type exotoxin that disrupts host signaling.
    explanation: >-
      Identifies pertussis toxin as the major AB5 exotoxin virulence factor that
      disrupts host signaling. Evidence source is OTHER as this is a review article.
  - reference: PMID:41893571
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Its enzymatic A subunit ADP-ribosylates the α-subunit of inhibitory G
      proteins (Gαi), preventing them from mediating receptor-induced inhibition of
      adenylyl cyclase (AC). This leads to unrestrained cAMP accumulation in host
      cells
    explanation: >-
      Details the molecular mechanism — ADP-ribosylation of Gαi causing
      unrestrained cAMP accumulation. Evidence source is OTHER as this is a review
      article.
  downstream:
  - target: Paroxysmal Coughing Illness
    description: >-
      Toxin-mediated disruption of host signaling produces the characteristic
      paroxysmal coughing illness.

- name: Paroxysmal Coughing Illness
  role: consequence
  description: >
    The clinical syndrome of pertussis is a paroxysmal coughing illness, classically
    with an inspiratory whoop and post-tussive emesis. In young infants it may
    manifest as cyanosis or facial flushing during coughing fits and apnea, and is
    associated with marked leukocytosis.
  biological_processes:
  - preferred_term: inflammatory response
    term:
      id: GO:0006954
      label: inflammatory response
    modifier: INCREASED
  locations:
  - preferred_term: respiratory system
    term:
      id: UBERON:0001004
      label: respiratory system
  evidence:
  - reference: PMID:41963827
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      presented with paroxysmal coughing
    explanation: >-
      Clinical cohort documenting paroxysmal coughing as the predominant
      presentation of pertussis. Evidence source is HUMAN_CLINICAL as this is a
      clinical cohort study.
  downstream: []

- name: Bacterial Ribosomal Translation (Macrolide Target)
  role: therapeutic_vulnerability
  conforms_to: "bacterial_protein_synthesis_inhibition#Bacterial mRNA Translation by the Ribosome"
  description: >
    B. pertussis depends on its bacterial ribosome for protein synthesis.
    Macrolides (e.g., azithromycin), the conventional antibiotics for pertussis,
    bind the 50S ribosomal subunit and block bacterial protein synthesis — the
    molecular target underlying antibiotic therapy (which reduces transmissibility
    more than it alters the toxin-driven cough once established).
  biological_processes:
  - preferred_term: translation
    term:
      id: GO:0006412
      label: translation
  evidence:
  - reference: PMID:24336183
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The ribosome is one of the main antibiotic targets in the bacterial cell.
    explanation: >-
      Establishes the bacterial ribosome as the target of macrolides and other
      protein-synthesis inhibitors, the step this node represents. Evidence source
      is OTHER as this is a review article.
  downstream:
  - target: Emerging Macrolide Resistance
    description: >-
      Macrolide resistance in B. pertussis erodes the efficacy of ribosome-targeting
      therapy.

- name: Emerging Macrolide Resistance
  role: adaptive_escape
  conforms_to: "bacterial_protein_synthesis_inhibition#Ribosomal Target Resistance"
  description: >
    Macrolide-resistant B. pertussis is an emerging concern in some regions, which
    can render azithromycin ineffective and shift treatment toward alternatives such
    as trimethoprim-sulfamethoxazole.
  biological_processes:
  - preferred_term: response to antibiotic
    term:
      id: GO:0046677
      label: response to antibiotic
  evidence:
  - reference: PMID:41963827
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      high-level resistance to azithromycin but sensitivity to
      trimethoprim-sulfamethoxazole, levofloxacin, doxycycline
    explanation: >-
      In vitro drug-susceptibility testing of B. pertussis isolates showing
      high-level azithromycin resistance with retained sensitivity to alternatives.
      Evidence source is IN_VITRO as this is an in vitro susceptibility assay of
      isolates (in this cohort all 25 isolates were azithromycin-resistant,
      grounding the "in some regions" caveat).
  downstream: []
phenotypes:
- category: Respiratory
  name: Whooping Cough
  description: >
    Paroxysmal coughing fits, classically followed by an inspiratory "whoop"; the
    defining manifestation of pertussis.
  phenotype_term:
    preferred_term: Whooping cough
    term:
      id: HP:0031247
      label: Whooping cough
  evidence:
  - reference: PMID:41963827
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      presented with paroxysmal coughing
    explanation: >-
      Most hospitalized cases presented with paroxysmal coughing. Evidence source
      is HUMAN_CLINICAL as this is a clinical cohort study.
- category: Gastrointestinal
  name: Post-tussive Vomiting
  description: >
    Vomiting after coughing paroxysms (post-tussive emesis), a characteristic
    feature of pertussis.
  phenotype_term:
    preferred_term: Post-tussive vomiting
    term:
      id: HP:0002013
      label: Vomiting
  evidence:
  - reference: PMID:41963827
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      post-tussive emesis
    explanation: >-
      Post-tussive emesis was documented in the clinical cohort. Evidence source is
      HUMAN_CLINICAL as this is a clinical cohort study.
- category: Respiratory
  name: Apnea
  description: >
    Apnea, particularly in young infants, is a dangerous manifestation of severe
    pertussis.
  phenotype_term:
    preferred_term: Apnea
    term:
      id: HP:0002104
      label: Apnea
  evidence:
  - reference: PMID:41963827
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      had apnea
    explanation: >-
      Apnea was documented among hospitalized pertussis cases. Evidence source is
      HUMAN_CLINICAL as this is a clinical cohort study.
- category: Respiratory
  name: Cyanosis
  description: >
    Cyanosis (or facial flushing) during coughing fits, especially in infants.
  phenotype_term:
    preferred_term: Cyanosis
    term:
      id: HP:0000961
      label: Cyanosis
  evidence:
  - reference: PMID:41963827
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      manifested cyanosis or facial flushing during coughing
    explanation: >-
      Over half of hospitalized cases manifested cyanosis or facial flushing during
      coughing. Evidence source is HUMAN_CLINICAL as this is a clinical cohort study.
- category: Hematologic
  name: Leukocytosis
  description: >
    Marked leukocytosis (with lymphocyte predominance) is characteristic of
    pertussis and elevated white cell count is a risk factor for severe disease.
  phenotype_term:
    preferred_term: Leukocytosis
    term:
      id: HP:0001974
      label: Increased total leukocyte count
  evidence:
  - reference: PMID:41963827
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      elevated white blood cell count
    explanation: >-
      Elevated white blood cell count was an independent risk factor for severe
      pertussis. Evidence source is HUMAN_CLINICAL as this is a clinical cohort
      study.
- category: Constitutional
  name: Fever
  description: >
    Low-grade fever may accompany pertussis, though it is often absent.
  phenotype_term:
    preferred_term: Fever
    term:
      id: HP:0001945
      label: Fever
treatments:
- name: Azithromycin
  description: >
    Macrolide antibiotic that binds the 50S bacterial ribosome and inhibits protein
    synthesis; the conventional antibiotic for pertussis, primarily reducing
    transmissibility. Emerging macrolide-resistant B. pertussis in some regions can
    necessitate alternatives such as trimethoprim-sulfamethoxazole.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: azithromycin
      term:
        id: CHEBI:2955
        label: azithromycin
  target_mechanisms:
  - target: Bacterial Ribosomal Translation (Macrolide Target)
    treatment_effect: INHIBITS
    description: >-
      Azithromycin binds the 50S ribosome and arrests B. pertussis protein
      synthesis, clearing carriage and reducing transmission.
- name: Pertussis Vaccination
  description: >
    Acellular pertussis vaccination (DTaP in infants/children, Tdap boosters
    including maternal immunization) is the key strategy for preventing severe
    pertussis, particularly in young infants.
  treatment_term:
    preferred_term: vaccination
    term:
      id: MAXO:0001017
      label: vaccination
  evidence:
  - reference: PMID:41963827
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      timely completion of the primary pertussis vaccination series in infants
      remains a key strategy for preventing severe pertussis
    explanation: >-
      The cohort concludes that timely primary pertussis vaccination is key to
      preventing severe disease. Evidence source is HUMAN_CLINICAL as this is a
      clinical cohort study.
notes: >
  Created as part of the Respiratory Infections project (vaccine-preventable
  bacterial respiratory infection). Conforms to the
  bacterial_protein_synthesis_inhibition module (ribosomal macrolide target +
  emerging resistance). Toxin-mediated pathogenesis (pertussis toxin / adenylate
  cyclase toxin) is the core mechanism. The infectious_agent (NCBITaxon) block was
  omitted at creation and Bordetella pertussis is described in the text.